Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(11):86-99. doi: 10.17116/jnevro202512511186.
ABSTRACT
OBJECTIVE: To search for evidence-based data on the efficacy of Gliatilin (choline alfoscerate) in patients with cognitive impairments.
MATERIAL AND METHODS: The study focused on sources covering the efficacy of drug therapy for vascular and post-traumatic cognitive impairments not reaching the level of dementia (mild cognitive impairment, MCI) using Gliatilin. A systematic literature review, paired meta-analysis, metaregression, and subgroup analyses were conducted. A total of 10 studies strictly meeting the objective were selected.
RESULTS: The study demonstrated a statistically significant effect of Gliatilin in treating patients with vascular or post-traumatic MCI. It also showed statistically significant superiority of its parenteral (or parenteral followed by oral) administration (for at least 28 days) compared to basic therapy in patients with vascular MCI.
CONCLUSION: The main challenge during the analysis was methodological, population, and statistical heterogeneity, which required not only the use of a random effects model but also active search and exclusion of some sources. However, despite several limitations, the internal consistency and absence of contradictions in the analysis results demonstrated the robustness of the evidence obtained. The inclusion of a highly effective drug in the specialized medical care system will ensure the availability of cognitive impairment treatment programs and improve patients’ quality of life.
PMID:41362980 | DOI:10.17116/jnevro202512511186
